Index

abridged life tables, 84, 87
accelerated failure time (AFT) model, 243
  exponential, 246
  extended generalized gamma, 261
  log-logistic, 264
  lognormal, 258
  Weibull, 255
additive effect, 434
adequacy assessment, 317
adjusted covariates, 271, 303
adjusted OR, 405
age-related macular degeneration (AMD), 38, 41
data, 42
  risk factors, 46
age-specific failure rate, 11
Akaike, H., 217
Akaike information criterion (AIC), 216, 217,
  272, 274
albumin and creatinine ratio, 33
albuminuria, 37
allele, 434
Altshuler, B., 113
Alzheimer’s disease, 143
aluminum coupon, 152
American Diabetes Association (ADA), 40
Ananth, C.V., 427
Anderson–Gill model, 364
angina pectoris, 93, 106
animal leukemia system, 136
annual survival ratio, 96
anticancer drugs, 136
asymptotic likelihood inference, 161, 207, 216,
  242, 261, 326, 418
autoregressive (AR), 433
  first-order autoregressive (AR(1)), 433–7
average remaining lifetime, 89
Bacillus Calmette–Guerin (BCG), 19
backward selection procedure, 271
Bartholomew, D.J., 171
baseline examination, 30, 33, 38, 46
baseline hazard function, 283
baseline measurements, 392
Bates, D.M., 373
bathtub curve, 13
Bayesian information criterion (BIC), 214,
  216, 217, 271, 272, 274
binary outcomes, 384
binomial distribution, 101, 102, 393, 401, 405,
  412, 420, 421, 437, 440
bladder cancer, 215, 338, 355
body mass index (BMI), 33, 50
BOUNDS, 377, 378, 380, 381
breast cancer, 97, 98
Breslow, N., 80, 249, 291, 309
Butt, A.L., 41
Buzdar, A.U., 294
calculator, 50, 317
cancer of rectum, 26, 28
cancer of rectum in Connecticut, 125, 127
cardiovascular disease (CVD), 33, 296, 347,
  422
case–control study, 405
CATMOD, 397, 426
censored observations, 2
  progressively censored data, 4
  singly censored data, 3
censoring
  interval, 4, 5
  left, 4
  random, 4
  right, 4
  type I, 2
  type II, 3
  type III, 4
census data, 84
chi-square test, 385, 388
chronic leukemia, 143
COGLIT, 397, 415, 417
cluster, 370, 371, 373, 381
Cochran, 391
cohort life table, 84
cohort study, 33, 46, 304, 338, 373, 392, 412, 432, 435
common coefficients, 359
comparison of K samples, 128
comparison of Nelson–Aalen and product-limit estimates, 83
correlation coefficient, 433–5
Corynebacterium parvum (C. parvum), 19, 20
covariance matrix, 163
  estimated, 163, 165, 172, 173, 210, 245
covariance structures, 433
  autoregressive, 433, 435, 436
  exchangeable, 433, 436, 439, 440
  independent, 433, 436, 439, 440
  kinship, 434, 438–40
  unstructured, 433
covariates-adjusted survivorship function, 311
covariates-specific survivorship function, 314
Cox, D.R., 111, 112, 119, 200, 232, 274, 282,
Cox–Mantel test, 111
Cox’s F-test, 109, 119, 232
Cox–Snell residual, 200, 274, 321
COXPH, 294, 301, 313, 327, 345, 346, 349, 353
COXREG, 294, 313, 327, 345, 349, 353
criminology, 1
criterion, 216, 217
cross-product ratio, 389
Crowley, J., 80, 201, 322
crude death rates, Oklahoma and Montana, 106
crude rate, 99, 101
cumulative hazard function, 13
cumulative incidence, 49
cumulative survival rate, 9
current life table, 84
decreasing hazard, 12
degrees of freedom, 115, 119, 124, 128, 151, 166, 168, 175, 181, 208, 210, 232, 236, 245, 246, 388, 391, 396
Delong, D.M., 291, 300
density curve, 10
density function
  definition of, 10
  types of
    exponential, 134
    extended generalized gamma, 153
    gamma, 149
    generalized gamma, 152
    log-logistic, 153
    lognormal, 143
    Weibull, 139
density transformation rule, 244
development of a disease, 1
development of tumor, 24
deviance residual, 322
diabetes (DM), 30, 33, 37
dichotomous outcomes, 384
diet and tumor, 24
  data, 25
direct method, 100
direct standardized rate, 100, 101
disease-free time, 108
distinct survival time, 69
distribution of survival time, 8
distribution with step hazard function, 155, 158
density function, 158
  hazard function, 158
  survivorship function, 158
dummy variables, 240
Efron, B., 292
empirical Bayesian estimators, 375
epidemiologic studies, 1
Epstein, B., 166, 169, 174, 175
Erlangian distribution, 149
estimated covariance matrix, 163
estimation procedures, 161
analytical, 161
exponential, 165
with censored observations, 168
progressively censored, 170
singly censored, 168, 170
without censored observations, 166
two-parameter exponential, 173
extended generalized gamma, 183
Gompertz, 185, 186
log-logistic distribution, 184
lognormal, 180
with censored observations, 182
without censored observations, 180
Weibull, 162, 178
with censored observations, 179
progressively censored, 179
singly censored, 179
without censored observations, 173
graphical, 161, 186
advantages, 187
hazard plotting, 493
exponential, 194
log-logistic, 199
lognormal, 198
Weibull, 195
probability plotting, 188
exponential, 188
log-logistic, 192
lognormal, 191
Weibull, 189
event-free times, 370
exact observations, 2
exact partial likelihood function, 291, 296
excess residuals, 322
exchangeable covariance structure, 433
expectation of life, 85, 87
expected numbers, 115
expected rate, 97
exponential distribution, 133, 159, 165
coefficient of variation, 134
density function, 134
cumulative distribution, 134
cumulative hazard function, 134
goodness-of-fit test, 211
hazard function, 134
mean, 134
median, 134
survivorship function, 134
test for equality of two distributions, 229, 232
two-parameter exponential distribution, 135
cumulative distribution function, 135
density function, 135
cumulative hazard function, 136
hazard function, 135
survivorship function, 135
unit exponential distribution, 134
extended families, 437
extended generalized gamma distribution, 152, 183, 184, 207, 209–13, 219, 220, 237, 261, 262, 273, 326
extended logrank test, 129
F distribution, 119
F-statistic, 119
family study, 370, 371, 373, 376, 379, 432, 434, 437, 439
fasting plasma glucose, 429
Feinleib, M., 146
first-order autoregressive, 50, 433
Fleming, T.R., 322, 365
force of mortality, 11
frailty model, 371
based on the accelerated failure time (AFT) models, 371, 379, 381
based on the proportional hazards, 371, 377
estimation, 372–81
Freireich, E. J., 104
gamma distribution, 148, 160
cumulative distribution function, 150
density function, 149
hazard function, 150
survivorship function, 150
gamma function, 140
gap time, 360
Gauss–Hermite quadrature numerical integration method, 373, 377, 379
Gehan’s generalized Wilcoxon test, 109
generalized gamma distribution, 148, 151
goodness-of-fit test, 206, 212, 219
test for equality of two distributions, 236
generalized linear models, 51, 52
generalized logistic regression model, 421
GENMOD, 433, 437, 440
GLIMMIX, 439, 440
GLM, 397, 401, 405, 412, 421
Gompertz distribution, 155, 156, 186
density function, 157
hazard function, 156
survivorship function, 156
Gompertz–Makeham distribution, 225
goodness-of-fit tests, 213, 214, 216, 273, 275
Grambsch, P.M., 323
Greenland, S., 421
Greenwood, M., 93
guarantee time, 136, 141
Haenszel, W., 123
Harrington, D.P., 322
Harter, H.L., 235
hazard function
definition of, 11
exponential, 135
gamma, 150
log-logistic, 154
lognormal, 198
Weibull, 195
hazard plotting, 193
exponential, 194
log-logistic, 199
lognormal, 198
Weibull, 195
hazards ratio or relative hazards or relative risks, 247, 253, 254, 256, 257, 283–5, 289, 290, 303, 305, 308
Health Care Financing Administration (HCFA), 84
hepatitis B virus (HVB), 155
Herzberg, A.M., 355
heterogeneity, 23
Hetzel, A.M., 102
Hodgkin’s disease, 143
Hollander–Proschan’s test, 220
Hosmer–Lemeshow test of goodness-of-fit, 396, 410
hypergeometric distribution, 124
hypernephroma, 54, 55, 131, 160
hypertension, 46
risk factors, 46, 49
impaired fasting glucose, 429
incidence rate, 33
incomplete gamma function, 150
increasing hazard, 12
index function, 53
indicator variable, 247, 251, 345
indirect method, 101
indirect standardized rate, 101, 102
industrial reliability, 1, 149
information matrix, 289, 328
instantaneous failure rate, 11
interaction, 241, 317, 399
interval-censored observations, 155, 164, 243
joint log-likelihood function, 226
joint probability, 162
Kalbfleisch, J.D., 75, 212, 262, 310
Kalbfleisch and Prentice estimator, 311
Kaplan–Meier method, 72, 80, 200, 220, 321
Khoury, M.J., 434, 438
kinship coefficient, 434
Klein, J.P., 372
Kleinbaum, D.G., 421
KM, 76, 117
K-sample test for censored data, 128
laboratory studies, 1
large extended families, 434
large sample approximate variance, 92
Lee, E.T., 30, 33, 314
left censored observation, 5, 164, 244
Lemeshow, S., 396, 410
Liang, K.Y., 370, 432, 433, 436
life expectancy, 89
life table estimate of density function, 92
life table estimate of hazard function, 92
life-table estimates, 68
life tables, 84
abridged, 84
clinical, 89
cohort, 84
current, 84
population, 83
U.S., 1959–61, 17
U.S., 2000, 85
LIFEREG, 165, 172, 173, 180, 183–5, 219, 252, 255, 260, 264, 267, 273, 278, 301
LIFETEST, 76, 83, 96, 117, 279, 327
lifetime of devices, 1
likelihood function, 162, 164, 166, 168, 170, 178, 182, 183, 226, 230
likelihood ratio test, 226, 229, 236, 266, 395, 397
linear exponential distribution, 155, 156
density function, 156
hazard function, 155
mean, 156
survivorship function, 156
linear interpolation, 70, 93
link function, 417
complementary log-log, 418, 428, 430
identity, 434
inverse normal or probit or normit, 417, 419, 428, 430
logit, 417, 427
location parameter, 145
log-gamma distribution, 261, 372
log-likelihood, 162
log-likelihood ratio statistic, 211–14, 216, 217, 220, 246
log-logistic distribution, 153, 160, 184, 192, 199, 264
cumulative hazard function, 154
density function, 153
goodness-of-fit test, 219
hazard function, 154
survivorship function, 153
log odds, 393
log survival function, 113
LOGISTIC, 397, 401, 404, 410, 419, 420, 426, 431
logistic distribution, 281
logistic regression, 392, 397, 401, 412, 420
conditional, 405
n1:n0 matched design or stratified design, 409
1:R matched design, 408
dichotomous outcomes, 384
polychotomous outcomes, 384, 421
nominal, 421
ordinal, 427
logistic transform, 393
lognormal distribution, 160, 198, 201, 212, 237, 258
density function, 143
goodness-of-fit test, 212, 218
survivorship function, 143
three-parameter, 145
density function, 144
survivorship function, 144
logrank test, 112, 113, 129
longitudinal study, 46, 337, 370, 381, 432, 435
lymphocytic leukemia, 146
MacMahon, B., 146
Mann–Whitney U-test, 109
Mantel, N., 110, 111, 113, 123
Mantel–Haenszel method, 123
Mantel’s procedure for Gehan’s Wilcoxon test, 110, 112
marginal likelihood function, 372–4, 379
marginal model, 352, 366, 432, 433, 435, 436, 438, 440
marginal partial likelihood function, 372, 373
martingale-based residuals of Lin, Wei and Ying, 328
supremum test, 329
martingale residuals, 322, 328
matched design, 408
1:1, 409
n1:n0, 409
1:R, 408
maximum likelihood estimate, 161
exponential, 165
extended generalized gamma, 183
Gompertz, 185
interval-censored data, 164, 243
left-censored data, 164, 244
log-logistic, 184
lognormal, 180
right-censored data, 161
two-parameter exponential, 173
Weibull, 178
mean survival time, 76
estimated, 79
variance, 79, 80
mean survival time limited, 79
median remaining lifetime, 93
median survival time, 21, 70
Medicare program, 84
Meier, 68, 69, 76, 80
melanoma, 20, 54
minimum survival time, 136, 173
missing data, 241
model selection method, 216, 270–272, 274
models for related observations, 370, 432
mono-tone, 164
Monte Carlo study, 92
MULTINOM, 397, 426
multinomial distribution, 210
multiple causes, 350,
multiple events, 354
multiple outcomes, 391, 421
multiplicative hazard function, 364
multiplicity, 111
myelocytic leukemia, 146
myeloma, 13
Nelson–Aalen estimates, 82
variance, 82
nesting distribution, 207, 216
Newton–Raphson iterative procedure, 163
NLMIXED, 374, 377, 378, 380, 381
nominal polychotomous outcomes, 421
model for, 421
nominal variable, 415
NOMREG, 397, 426
nonlinear effects, 241
nonparallel curves, 319
nonparametric methods, 68, 108
nonproportional hazards models, 337
  competing risks, 350
  recurrent events, 350
  related observations, 370
  stratified analysis, 346
  time dependent covariates, 337
  normal distribution, 110
    approximately, 110, 124, 166, 168, 171, 221
    asymptotically, 110, 111, 114, 310, 311
    standard, 258
  normal fasting glucose, 429
  normit function, 417
  NORMSDIST, 201
  number lost to follow-up, 90
  number withdrawn alive, 90, 91, 95
  numerical integration method, 373, 377
  numerical method, 162, 163

  observed numbers, 115
  observed rate, 97
  odds ratio (OR), 265, 266, 386, 388
  one-parameter exponential distribution, 165
  one-sided test, 208, 231, 232
  one-to-one pair matching, 409
  optimal subset of covariates, 270, 274, 338
  ordinal polychotomous outcomes, 421
    model for, 427, 428
  ovarian cancer, 105

  parametric methods, 226, 239
  parametric regression models, 239, 242
  parametric survival distributions, 133
  partial likelihood function, 286, 288, 291, 292,
    300, 302, 338, 351, 371
  Pearson, K., 150, 396
  pedigree, 437
  penalty, 217
  percentile, 73, 163, 167, 177, 208, 227, 373–6,
    395
  permutational distribution, 110
  permutational variance, 110
  Peterson, A.V., 354
  Peto and Peto’s generalized Wilcoxon test, 117,
    118, 121
  piece-wised exponential hazard function, 373
  PHREG, 294, 301, 306, 309, 313, 326, 334, 344,
    345, 348, 353, 362–4, 397, 415, 416
  Pike, M.C., 141
  PLUM, 397, 431
  Poisson approximation, 101
  Poisson distribution, 101, 102
  POLR, 397, 431
  polychotomous outcomes, 384
    nominal, 421
    ordinal, 427
  pooled sample, 110
  population and deaths in Japan and Chile, 107,
    1960
  population projection, 84
  pre-hypertension, 45
  preliminary examination of data, 240
  Prentice, R.L., 75, 122, 247, 354,
  Prentice, Williams and Peterson (PWP) model,
    354, 360
  probability density function, 10
  probability integral transformation, 375,
    378
  probability plotting, 186, 188
    exponential, 188
    log-logistic, 192
    lognormal, 147, 148, 191
    normal, 187
  Weibull, 189
  PROBIT, 397, 404
  probit function, 417, 428
  product-limit estimate, 69, 73, 75
    estimate of mean survival time, 76, 79
    variance, 74
    variance of estimated mean survival time, 79
  prognostic factors, 6, 32, 239, 285
  prognostic homogeneity, 21
  progressively censored data, 170, 176, 179,
    182, 183
  proportional frailty model, 371
  proportional hazards model, 247, 256, 282
    assessment of assumption, 317
    Cox–Snell, 321
    deviance and Martingale, 322
    Lin, Wei and Ying, 328
    check functional form of covariate, 328,
      329
    check proportional hazards assumption,
      328, 329
    by residuals, 319
    Schoenfeld, 322
    Breslow estimation, 309, 311
    confidence bands, 310
    confidence interval, 289
    continuous time scale, 291
    discrete time scale, 292
    estimation of survivorship function, 309
    estimation without ties, 286
    estimation with ties, 290
    identification of prognostic factors, 302
    Kalbfleisch and Prentice estimates, 310,
      311
    partial likelihood function, 288
    proportional odds model, 265, 427
    Proschan, F., 207, 220
    prospective studies, 392, 418
INDEX

random effect, 371, 372, 375, 376, 378
range, 163
Rayleigh distribution, 156
recurrent events, 353
reduced-sample estimate, 71
rejection regions, 111
related observations, 370, 432
relationships of survival functions, 15
relative survival, 30
relative survival rate, 96
residual maximum likelihood (REML), 372
residuals, 200, 327
Cox–Snell, 200, 274, 321
deviance, 322
Martingale, 322, 328
Schoenfeld, 322
weighted Schoenfeld, 323
retrospective study, 405
right censoring, 4, 161
risk calculator, 50, 317
risk factors, 239
risk factors for incident events, 33
risk set, 112, 286
Rodriguez, G., 372
Sacher, G.A., 92
Saunders, S.C., 148
scale parameter, 138, 150, 184, 190
Schoenfeld residual, 322
weighted, 323, 324
Schwarz, G., 216
score process, 328, 330, 332, 333
score statistic, 210, 218–20, 302
scores, 113, 118, 119, 128
shape parameter, 138, 150, 184, 190, 220, 262
Shryock, H.S., 28, 102
significant-level, 208, 227
Snell, E.J., 200
Sobel, M., 133
specific rates, 104
standard normal distribution, 111, 258
standardization, 100
standardized empirical score process, 328
standardized mortality (or morbidity) ratio (SMR), 98
standardized incidence ratio (SIR), 99
standardized rate and ratio, 98
direct method, 100
confidence interval, 101
variance, 101
indirect method, 100
confidence interval, 102
variance, 102
SIR, 99
SMR, 98
stationary population, 88
stepwise selection procedure, 272
stratified proportional hazards model, 346
stratum-specific coefficients, 359
stratum-specific underlying hazard, 354
stroke, 54, 64
subfailure, 149
submatrix, 208
supremum test, 329
SURVDIFF, 118
SURVFIT, 76
survival curve, 9
survivorship function
definition of, 8
estimation of, 69, 82, 89, 162, 244, 310
types
exponential, 134
gamma, 150
Gompertz, 156
log-logistic, 153
lognormal, 143
two-parameter exponential, 135
Weibull, 139
SURVREG, 165, 173, 180, 183, 185, 219, 229, 252, 261, 267
test of goodness-of-fit, 206, 207, 213, 214, 216, 273, 275, 322, 326, 410
test statistic, 110, 114
Therneau, T.M., 322, 323
Thoman, D.R., 234
tied survival times, 290
time-dependent covariates, 317, 337, 338, 345
time series, 434
Tsiatis, A.A., 396
tumor-free time, 28, 76, 77
tumor inoculum, 136, 204
tumor recurrent data, 358
two-sided test, 208, 231, 232
type-specific hazards, 350
unbiased estimate, 80, 174, 181, unconditional failure rate, 11
UNIVARIATE, 376
urinary albumin and creatinine ratio, 33

variable selection procedure, 270
  AIC, 217
  backward selection, 271
  BIC, 216
  forward selection, 271
  stepwise selection, 272
vector, 161
vital statistics, 84

Wald statistic, 208–10, 302
Wang, W., 46, 434
Wei, L.J., 328, 366
Wei, Lin and Weissfeld (WLW) model, 366
Weibull distribution, 138, 151, 152, 159, 269
coefficient of variation, 141

cumulative distribution function, 139
density function, 139
goodness-of-fit test, 226, 234
hazard function, 139
mean, 140
surviviorship function, 139
test for equality of two distributions, 233
three-parameter Weibull distribution, 141
density function, 141
hazard function, 141
survivorship function, 141
variance, 140
weighted Schoenfeld residuals, 325
Weissfeld, L., 366
Wilcoxon, F., 109, 117, 122
Williams, B.J., 354
Woold, B., 389

Zeger, S.L., 432, 433
Zelen, M., 136, 173, 268